Rapamycin-loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential wet age-related macular degeneration treatment: an in vivo study.
4 affiliations
- 1Department of Ocular Diseases, Nanchang Bright Eye Hospital, Nanchang, China.
- 2Department of Ophthalmology, Hainan General Hospital (Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China.
- 3Department of Ophthalmology, Baoding No.2 Central Hospital, Baoding, China.
- 4Department of Ophthalmology, Hainan General Hospital (Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China. [email protected].
Abstract
Wet age-related macular degeneration (Wet AMD) is a major cause of vision loss and has been linked to abnormal choroidal neovascularization (CNV). Current therapies require frequent intravitreal injections, which leads to poor patient adherence. Herein, this study was designed to investigate rapamycin-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles, which represent a sustained-release drug delivery system for wet AMD. The Rap@CS/PLGA NPs were synthesized using emulsion solvent evaporation, followed by coating with chitosan. The obtained Rap@CS/PLGA NPs exhibited a size of 265.9 ± 6.30 nm and encapsulation efficiency (EE) of 60.30 ± 1.20%. The drug release profile showed a biphasic pattern with reduced initial burst release (6 ± 0.6%) followed by sustained release (46 ± 4.1%) over 72 h, which indicates improved delivery control. In vitro cytotoxicity on ARPE and HUVEC cells showed minimal toxicity, with more than 85% viability at dosages up to 100 μg/mL. In vivo anti-angiogenic assays using the chick chorioallantoic membrane (CAM) model showed that the Rap@CS/PLGA group (13 ± 3 vessels) significantly reduced the vessel formation vs Rap (26 ± 2 vessels), confirming superior anti-angiogenic effects. Moreover, the laser-induced CNV mouse model, Rap@CS/PLGA NPs, significantly reduced levels of inflammatory cytokine (TNF-α and IL-6) and restored antioxidant enzyme (SOD, CAT). This showed that protection against oxidative stress in CNV-affected tissue promotes angiogenic gene expression (VEGFA, CCL2), while preserving retinal structure. These findings propose that Rap@CS/PLGA NPs can effectively and control drug delivery for wet-AMD with long-lasting efficacy.
Related
- Glutamine-Functionalized mRNA Lipid Nanoparticles Block HIF-1α-Dependent Glycolytic Adaptation to Sensitize Azelaic Acid Therapy in Colorectal Cancer
- Advances and mechanisms in the application and treatment of functionalized stem cells and their derivatives in allergic rhinitis
- Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration : A Post Hoc Analysis of the TENAYA and LUCERNE Trials
- PHGDH-Mediated Serine Metabolism in Nucleus Pulposus Cells Is a Potential Therapeutic Target for Intervertebral Disc Degeneration.
- Investigating potential molecular mechanisms linking 6PPD-quinone exposure to Intervertebral Disc Degeneration: A network toxicology, molecular docking, and molecular dynamics simulation study
BibTeX
@article{hu2026rapamycinloaded,
title = {{Rapamycin-loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential wet age-related macular degeneration treatment: an in vivo study.}},
author = {Yuan Hu and Lijuan Wei and Haijun Yang and Jianhong Sun and Donglei Li and Qian Liu},
journal = {Journal of materials science. Materials in medicine},
year = {2026},
month = jul,
doi = {10.1007/s10856-026-07060-z},
url = {https://europepmc.org/article/MED/42967969},
note = {CC BY},
}
RIS
TY - JOUR
TI - Rapamycin-loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential wet age-related macular degeneration treatment: an in vivo study.
AU - Yuan Hu
AU - Lijuan Wei
AU - Haijun Yang
AU - Jianhong Sun
AU - Donglei Li
AU - Qian Liu
PY - 2026
DA - 2026/07/25
JO - Journal of materials science. Materials in medicine
DO - 10.1007/s10856-026-07060-z
UR - https://europepmc.org/article/MED/42967969
AB - Wet age-related macular degeneration (Wet AMD) is a major cause of vision loss and has been linked to abnormal choroidal neovascularization (CNV). Current therapies require frequent intravitreal injections, which leads to poor patient adherence. Herein, this study was designed to investigate rapamycin-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles, which represent a sustained-release drug delivery system for wet AMD. The Rap@CS/PLGA NPs were synthesized using emulsion solvent evaporation, followed by coating with chitosan. The obtained Rap@CS/PLGA NPs exhibited a size of 265.9 ± 6.30 nm and encapsulation efficiency (EE) of 60.30 ± 1.20%. The drug release profile showed a biphasic pattern with reduced initial burst release (6 ± 0.6%) followed by sustained release (46 ± 4.1%) over 72 h, which indicates improved delivery control. In vitro cytotoxicity on ARPE and HUVEC cells showed minimal toxicity, with more than 85% viability at dosages up to 100 μg/mL. In vivo anti-angiogenic assays using the chick chorioallantoic membrane (CAM) model showed that the Rap@CS/PLGA group (13 ± 3 vessels) significantly reduced the vessel formation vs Rap (26 ± 2 vessels), confirming superior anti-angiogenic effects. Moreover, the laser-induced CNV mouse model, Rap@CS/PLGA NPs, significantly reduced levels of inflammatory cytokine (TNF-α and IL-6) and restored antioxidant enzyme (SOD, CAT). This showed that protection against oxidative stress in CNV-affected tissue promotes angiogenic gene expression (VEGFA, CCL2), while preserving retinal structure. These findings propose that Rap@CS/PLGA NPs can effectively and control drug delivery for wet-AMD with long-lasting efficacy.
SN - 0957-4530
SN - 1573-4838
ER -